Sanofi
Sanofi to add future payments onto Medivation offer, according to reports
June 23, 2016Research and Development, Sales and Marketing Medivation, Sanofi
Sanofi (NYSE: SNY) is considering adding future payments, tied to certain targets, to its proposed $9.3 billion takeover of US …
Nice backs two cancer drugs from Novartis
June 22, 2016Research and Development, Sales and Marketing AbbVie, Amgen, Humira, NICE, Novartis, Sanofi, lung cancer, skin cancer
The National Institute for Health and Care Excellence (Nice) has backed two drugs form Novartis (VTX: NOVN) for lung cancer …
Sanofi and Regeneron combo shows superiority in late-stage atopic dermatitis trials
June 6, 2016Research and Development, Sales and Marketing Dupilumab, Regeneron, Sanofi, atopic dermatitis, late stage trials
Sanofi (NYSE: SNY) and Regeneron (NASDAQ: REGN) have announced positive results from a Phase III trial evaluating dupilumab in patients …
Sanofi looks to set date for showdown with Medivation shareholders
June 2, 2016Sales and Marketing Medivation, Sanofi, hostile, record date, shareholders, takeover
Sanofi (NYSE: SNY) has announced that it has attempted to fix a record date with Medivation (NASDAQ: MDVN) where the …
Sanofi makes move to remove Medivation board; Medivation hits back
May 25, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Medivation, Sanofi, removal of board, takeover
Sanofi (NYSE: SNY) has taken their proposed takeover of Medivation (NASDAQ: MDVN) up several notches, with the French company filing …
US FDA advisors question usefulness of Sanofi’s combination diabetes therapy
May 24, 2016Manufacturing and Production, Research and Development, Sales and Marketing Sanofi, US FDA, diabetes, drug trial, regulation
US Food and Drug Administration staff questioned the benefits of French drugmaker Sanofi’s (Euronext: SAN) diabetes drug candidate as well …
Sanofi to replace entire Medivation board to drive sale, according to reports
May 16, 2016Manufacturing and Production, Research and Development, Sales and Marketing Medivation, Sanofi, replace board, takeover
Reports have emerged that Sanofi is looking to step up its efforts to take over oncology firm, Medivation, as it …
Sanofi Files Hart-Scott-Rodino notification for Medivation acquisition
May 13, 2016Medical Communications, Sales and Marketing M&A, MA, Medivation, Sanofi, deal
French drugmaker Sanofi (Euronext: SAN) on Friday said it has filed a premerger notification with the US Department of Justice Antitrust …
Medivation maybe mulling sale as bidding race heats up – Reports
May 10, 2016Manufacturing and Production, Research and Development, Sales and Marketing Amgen, Deals, M&A, MA, Medivation, Pfizer, Sanofi
Cancer drugmaker Medivation (Nasdaq: MDVN) is evaluating a potential sale following the recent string of offers from big pharma firms, …
NICE recommends Sanofi, Amgen cholesterol drugs
May 6, 2016Medical Communications, Sales and Marketing Amgen, Draft Guidance, NHS, NICE, Repatha, Sanofi, cardiovascular disease, cholesterol, final draft guidance, high cholesterol, praluent, recommendation, treatment
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending two new drugs for the …
Focus: Medivation tug-of-war rumbles on
May 6, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, AstraZeneca, Medivation, Pfizer, Sanofi, billion dollar, competition, oncology, pipeline, promising, takeover, tug of war
Medivation (NASDAQ: MDVN) has been making all the headlines as a list of suitors’ line up, all vying to secure …
Amgen looking to join the fray, mulling Medivation bid – Reports
May 5, 2016Research and Development, Sales and Marketing Amgen, AstraZeneca, Deals, M&A, MA, Medivation, Pfizer, Sanofi
Biotech firm Amgen (Nasdaq: AMGN) is mulling a bid for Medivation (Nasdaq: MDVN), the latest to join the growing list …
Sanofi sends letter to Medivation board; claims shareholders want takeover
May 5, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Medivation, Sanofi, board, brandicourt, hostile, shareholders, takeover
The CEO of Sanofi has issued a strongly worded letter to the board at Medivation, indicating that shareholders support their …
Pfizer joins the race, bids for Medivation – Reports
May 4, 2016Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, Deals, M&A, MA, Medivation, Pfizer, Sanofi
US pharma giant Pfizer (NYSE: PFE) is rumoured to have joined the list of suitors vying for the Medivation (Nasdaq: …
Board at Medivation unanimously reject Sanofi bid
April 29, 2016Medical Communications, Sales and Marketing Medivation, Sanofi, board, hostile, rejection, takeover
The board at Medivation has unanimously rejected the $9.8 billion takeover bid from Sanofi. They declare that Sanofi’s bid of …
Latest content
Five Facts about cardiovascular disease
Artificial hearts: a century of innovation
